Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leading Cancer Researcher Appointed NIMHD Clinical Director

Published: Friday, January 25, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Dr. Reed will oversee outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

The National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health has announced that Eddie Reed, M.D., an award-winning physician and internationally recognized cancer researcher, will serve as the clinical director for the NIMHD Intramural Research Program.

“Dr. Reed is a world renowned oncologist with extensive experience managing clinical trials and translating science into health,” said NIMHD Director John Ruffin, Ph.D.

Ruffin continued, “The breadth of his knowledge of health disparities and public health and the depth of his experience in cancer pharmacology will serve us well as we build the clinical research program within the NIMHD Intramural Research Program.”

Prior to joining NIMHD, Dr. Reed most recently served as professor of oncologic sciences and Abraham Mitchell Distinguished Investigator at the University of South Alabama’s Mitchell Cancer Institute, Mobile, where he has worked closely with the state of Alabama on life-saving cancer screening and control programs.

Dr. Reed has previously served as a tenured scientist, chief of the Clinical Pharmacology Branch, and chief of the Ovarian Cancer and Metastatic Prostate Cancer Clinic in the Division of Clinical Science at the National Cancer Institute (NCI); director of the Mary Babb Randolph Cancer Center at West Virginia University, Morgantown; and director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention.

Dr. Reed’s clinical research has primarily been focused on DNA damage and repair in cancer cells in response to pharmacological anticancer agents.

He has conducted more than four dozen phase I or phase II clinical trials of these agents and received two United States Public Health Service Commendation Medals for his work on the clinical development of the powerful anti-cancer agent, paclitaxel.

Paclitaxel is used to treat a variety of cancers including lung, breast, ovarian, and head and neck cancers. He has also collaborated on many public health cancer prevention, screening, and control programs throughout his career many of which were focused on reducing health disparities.

Dr. Reed received his undergraduate degree from Philander Smith College in Little Rock, Ark., and his medical degree from Yale University School of Medicine in New Haven, Conn. He completed his internship and residency at Stanford University in Palo Alto, Calif., and a fellowship at NCI in Bethesda, Md.

He is board certified in internal medicine and has been listed as a Top Doctor by the US News and World Report. He served on the Institute of Medicine’s National Cancer Policy Forum from 2005-2008. He has also served on the National Advisory Council on Minority Health and Health Disparities.

As clinical director, Dr. Reed will oversee a combination of studies including outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

He will build a multi- and inter-disciplinary research program geared to translating basic research into clinical trials and ultimately interventions.

He will lead the NIMHD effort in enhancing the recruitment and retention of minorities and other underserved populations in clinical trials.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Thursday, October 27, 2016
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Thursday, October 20, 2016
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Friday, October 14, 2016
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Friday, September 30, 2016
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Tuesday, August 23, 2016
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Thursday, August 04, 2016
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Thursday, July 28, 2016
NIH-Funded Center to Study Inefficiencies in Clinical Trials
Researchers at the Duke Clinical Research Institute (DCRI) and Vanderbilt University Medical Center (VUMC) have received a major federal grant to study how multisite clinical trials of new drugs and therapies in children and adults can be conducted more rapidly and efficiently.
Thursday, July 07, 2016
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
Wednesday, July 06, 2016
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
Tuesday, May 10, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!